Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
Engel SS., Suryawanshi S., Stevens SR., Josse RG., Cornel JH., Jakuboniene N., Riefflin A., Tankova T., Wainstein J., Peterson ED., Holman RR., TECOS Study Group None.
AIMS: To characterize the incidence of diabetes-associated complications and assess the safety of sitagliptin in participants with chronic kidney disease (CKD) in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). MATERIALS AND METHODS: For participants with baseline eGFR measurements (n = 14 528), baseline characteristics and safety outcomes were compared for the CKD cohort (eGFR